Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy

NCT03502031 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

72

Enrollment

OTHER

Sponsor class

Conditions

Renal Insufficiency, Chronic
Diabetic Nephropathy Type 2

Interventions

DRUG: Renin-Angiotensin (RAAS) alone
DRUG: Renin-Angiotensin (RAAS) blockers in combination with Spironolactone

Sponsor

James A. Tumlin, MD

Collaborators

[object Object]